1,721,724 research outputs found
Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Response to Jeganathan, Cheung and Wong.
No full text
Effetto della supplementazione con vitamina D3 sul rischio di insorgenza di diabete tipo 2: stiamo sovrastimando i suoi possibili benefici extra-scheletrici?
No full textLa carenza di vitamina D è stata associata alla presenza di molteplici patologie croniche non scheletriche (tra cui la malattia cardiovascolare, ipertensione, epatopatia steatosica non alcolica, alcune neoplasie e diabete), suggerendo la possibilità che tale vitamina possa svolgere numerosi effetti pleiotropici a livello extra-scheletrico, grazie alla distribuzione ubiquitaria del suo recettore 1-3. Tra queste patologie croniche non scheletriche che sono potenzialmente associate a ridotti livelli circolanti di vitamina D, il diabete mellito tipo 2 (T2DM) ha rappresentato uno dei più importanti focus della ricerca scientifica nell’ultimo decennio 4. Diversi studi epidemiologici hanno documentato che i pazienti con T2DM hanno livelli circolanti di vitamina D ridotti rispetto alla popolazione non diabetica (paragonabile per età, sesso e grado di obesità) e che bassi livelli di vitamina D si associano a una maggior prevalenza di complicanze croniche micro- e macro-vascolari del diabete 4-6. In modelli sperimentali è stato inoltre dimostrato che ridotti livelli di vitamina D si associano ad aumentata resistenza insulinica e alterata secrezione insulinica da parte della beta cellula oltre che a elevati livelli di diversi fattori pro-coagulanti e markers infiammatori, e che la maggior parte di tali alterazioni migliorano dopo somministrazione di vitamina D3 2,4,
Risk of ischemic stroke and decreased serum bilirubin levels: is there a causal link? [Editorial]
No full textnon
Polycystic Ovary Syndrome
No full textIn their review article on the polycystic ovary syndrome, McCartney and Marshall (July 7 issue) did not address the topic of nonalcoholic fatty liver disease. Several studies have recently shown that the prevalence of nonalcoholic fatty liver disease is markedly increased among women with the polycystic ovary syndrome, independent of overweight or obesity and other coexisting components of the metabolic syndrome, and that these women are more likely to have the more severe forms (nonalcoholic steatohepatitis, advanced fibrosis, and cirrhosis).2 Accumulating evidence also suggests that nonalcoholic fatty liver disease exacerbates hepatic and peripheral insulin resistance, confers a predisposition to atherogenic dyslipidemia, and causes the release of several proinflammatory, procoagulant, and profibrogenic mediators that may play important roles in the pathophysiology of the polycystic ovary syndrome and its related complications (principally cardiovascular disease and diabetes). These findings call for a more active and systematic search for nonalcoholic fatty liver disease in patients with the polycystic ovary syndrome
Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus?
No full textNon-alcoholic fatty liver disease (NAFLD) has become one of the most important causes of chronic liver disease in Western countries (1). The increasing prevalence of this liver disease parallels the global epidemics of both obesity and type 2 diabetes (T2DM) in many parts of the world (1). NASH is also projected to become the most common indication for liver transplantation in the near future (1). A 2016 meta-analysis of 86 epidemiological studies (including a sample size of nearly 8,500,000 subjects from 22 countries) has estimated that up to a quarter of the world’s adult population [25.2%, 95% confidence intervals (CI): 22.1–28.7%] has NAFLD (2). This liver disease was common throughout the world, but was particularly frequent in South America (31%), the Middle East (32%) and North America (24%), whereas it showed the lowest frequency in Africa (13%) (2)
- …
